Hyperkalemia: Clinical Trials

16 trials for Hyperkalemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed. 16 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 316Completed 16
Phase 21Completed 1

Follow Hyperkalemia: new trials by email Literature Review of Hyperkalemia trials Research Report on Hyperkalemia

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B) - Hyperkalemia, Renal Insufficiency, Chronic
Phase 3CompletedVifor Fresenius Medical Care Renal Pharma2622022-02-102026-04-13
Lokelma for RAAS Maximisation in CKD & Heart Failure.
Lokelma Oral Product - Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction
Phase 3CompletedSt George's, University of London1122022-01-192026-04-27
A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia
Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes, Placebo - Hyperkalemia
Phase 3CompletedZeria Pharmaceutical852021-08-032023-04-20
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.
Sodium Zirconium Cyclosilicate 5g, Sodium Zirconium Cyclosilicate 10g, Placebo - Hyperkalemia
Phase 3CompletedAstraZeneca2702021-05-062025-05-14
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
Sodium Zirconium Cyclosilicate, Placebo - Hyperkalemia
Phase 3CompletedAstraZeneca1342020-11-162023-03-28
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Patiromer, Placebos - Hyperkalemia
Phase 3CompletedVifor Pharma, Inc.11952019-04-242023-02-24
A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.
Placebo, Sodium Zirconium Cyclosilicate (ZS) - Hyperkalemia
Phase 3CompletedAstraZeneca1962017-12-142020-02-20
Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
Zirconium Cyclosilicate - Hyperkalemia
Phase 3CompletedAstraZeneca1502017-09-042020-05-01
ZS Ph2/3 Dose-response Study in Japan
Sodium Zirconium Cyclosilicate (ZS) 5g, Sodium Zirconium Cyclosilicate (ZS) 10g, Placebo - Hyperkalemia
Phase 2 / Phase 3CompletedAstraZeneca1032017-06-142019-05-20
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia
Sodium Zirconium Cyclosilicate (ZS) 10g, Sodium Zirconium Cyclosilicate (ZS) 5g, Placebo - Hyperkalemia
Phase 3CompletedAstraZeneca2672017-03-032020-08-19
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
Sodium zirconium cyclosilicate - Sodium Zirconium Cyclosilicate, Hyperkalemia
Phase 3CompletedGuangdong Provincial People's Hospital622016-11-012022-05-19
Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months
Sodium Zirconium Cyclosilicate - Hyperkalemia
Phase 3CompletedZS Pharma, Inc.7512014-06-302018-06-27
Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
Sodium Zirconium Cyclosilicate - Hyperkalemia
Phase 3CompletedZS Pharma, Inc.1232014-05-312018-08-15
Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
Sodium zirconium cyclosilicate, Placebo - Hyperkalemia
Phase 3CompletedZS Pharma, Inc.2582014-03-312018-12-07
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Patiromer, Placebo - Chronic Kidney Disease (CKD), Hyperkalemia (HK)
Phase 3CompletedRelypsa, Inc.2432013-02-012021-06-03
Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
Zirconium silicate (acute phase), Zirconium silicate (subacute phase), Placebo (acute phase) - Hyperkalemia
Phase 3CompletedZS Pharma, Inc.7542012-11-302018-10-12

Narrower conditions

Renal Insufficiency, Chronic (4)  ·  Acute Kidney Injury (1)  ·  Heart Failure (1)  ·  Hyperparathyroidism, Secondary (1)  ·  Hypertension (1)  ·  Pseudohypoaldosteronism (1)

Broader conditions

Metabolic Diseases (16)  ·  Nutritional and Metabolic Diseases (16)  ·  Water-Electrolyte Imbalance (16)  ·  Chronic Disease (4)  ·  Disease Attributes (4)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Kidney Diseases (4)  ·  Male Urogenital Diseases (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Renal Insufficiency (4)  ·  Urogenital Diseases (4)  ·  Urologic Diseases (4)  ·  Cardiovascular Diseases (1)

Interventions

sodium zirconium cyclosilicate (10)  ·  Suspensions (2)  ·  patiromer (2)  ·  zircon (2)  ·  Calcium (1)  ·  Streptozocin (1)

Sponsors

AstraZeneca (6)  ·  ZS Pharma, Inc. (4)  ·  Guangdong Provincial People's Hospital (1)  ·  Relypsa, Inc. (1)  ·  St George's, University of London (1)  ·  Vifor Fresenius Medical Care Renal Pharma (1)  ·  Vifor Pharma, Inc. (1)  ·  Zeria Pharmaceutical (1)

Countries

United States (7)  ·  Japan (5)  ·  Australia (4)  ·  United Kingdom (4)  ·  China (3)  ·  Russia (3)  ·  South Africa (3)  ·  Czechia (2)  ·  Georgia (2)  ·  Germany (2)  ·  Hungary (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Serbia (2)  ·  Ukraine (2)

Top investigators

Henrik Rasmussen, MD, PhD (3)  ·  Debasish Banerjee, MD FRCP (1)  ·  Henrik Rasmussen, MD (1)  ·  Julian Platon, MD, PhD (1)  ·  Shuangxin Liu, Ph.D (1)  ·  Steven Fishbane, MD (1)  ·  Yusuke Tomioka (1)  ·  Zhaohui Ni (1)

Results publications

PMID 32588430, PMID 31791288, PMID 25402495, PMID 25415807, PMID 29728199, PMID 32030422, PMID 32779057, PMID 33098526, PMID 33608263, PMID 35135481, PMID 35900838, PMID 37385905, PMID 39112102, PMID 39159624, PMID 39340493, PMID 39969301, PMID 41957746

NIH funding

2017 (1), 2018 (1)